Similar to endocrine therapy or anti-HER2 therapy, which requires determination of ER/PR or HER2 expression in breast cancer, respectively, it is necessary to identify biomarkers in TNBC to correlate the outcome of anti-Src therapy. Here, SRC is linked to breast cancer.